BioMarin To Report Revenue In-line With Consensus, Wedbush Says

By: via Benzinga
In a report published Friday, Wedbush Morgan analyst Liana Moussatos maintained a Neutral rating on BioMarin Pharmaceutical Inc (NASDAQ: ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.